Biotech Values

[biomaven0]

It is the case that there are folks from the Phase I that have continued to do well on 15mg - and those were patients who were third line.

Based on the preclinical work, most mutations increase the dose you need. So it stands to reason that naive patients should be able to get away with a lower dose.

In retrospect, the Tefferi paper pointing out the thrombogenic issues with Tasigna should have been a warning sign.

I also wonder if the shorts filed a FOIA to see reported SAEs and so had some advance warning of this.

Peter